First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2009-05-12 07:20:11Open Document File Size: 571,43 KBShare Result on FacebookCityNorwich / /CompanyMRC Technology / Comprehensive Spending Review / NIHR / NHS Health Research Delivery Group / /CountryUnited Kingdom / /CurrencyGBP / / / /IndustryTermhealthcare innovation / biotechnology industries / conventional chemical compounds / healthcare delivery / healthcare / healthcare industries / pharmaceuticals industry / pharmaceuticals / healthcare research performance / healthcare product development process / wider healthcare economy / /MedicalConditionparticular disease / illness / lack of coordination / disease / diseases / each disease / /MedicalTreatmentstem cell therapies / gene therapy / innovative therapies / /OrganizationHer Majesty’s Stationery Office / National Institute of Health / Dept of Health / Stationery Office / UK Government / Medical Research Council / OSCHR Board / Translational Medicine Funding Board / Executive Agency / Department of Health / NHS / National Health Service / /PersonIlona Blue / Paul Devenish / Caroline Barr / John Connolly / Alison Austin / Scienti / Dan Micklethwaite / David Cooksey / / /Positiondriver / c Adviser / acting head / Chancellor / gov. uk For / Chief / gov. uk ISBN-10 / Executive / UK Health Research Funding Executive / Chancellor of the Exchequer / representative / gov. uk HM Treasury / Controller / /PublishedMediumthe Comprehensive Spending Review / /Technologybiotechnology / stem cells / gene therapy / biopharmaceuticals / drug development / /URLhm-treasury.gov.uk / /SocialTag |